|
Match
|
Document |
Document Title |
|
|
US20090286763 |
AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS AND USES THEREOF
The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical...
|
|
|
US20090286762 |
Pharmaceutical Formulations Comprising Azelastine and a Corticosteroid for the Treatment of Inflammatory or Allergic Conditions
The present invention relates to pharmaceutical formulations comprising an anti-inflammatory glucocorticoid compound of formula (II), (III), (IV)
or a solvate thereof
and a compound for...
|
|
|
US20090286761 |
Anti-Proliferative and Anti-Inflammatory Agent Combination for Treatment of Vascular Disorders with an Implantable Medical Device
A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by...
|
|
|
US20090285900 |
COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent...
|
|
|
US20090285899 |
COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A METHYLXANTHINE DERIVATIVE FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent...
|
|
|
US20090285898 |
COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH AN ANTICHOLINERGIC BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent...
|
|
|
US20090285811 |
ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE GLUCOCORTICOID STEROIDS
The present invention relates to new glucocorticoid steroid modulators of glucocorticoid receptor, pharmaceutical compositions thereof, and methods of use thereof.
|
|
|
US20090281069 |
ORGANIC COMPOUNDS
The present invention relates to compounds of the formula;
and their use in therapy.
|
|
|
US20090280177 |
Pharmaceutical preparation for treating fibromyalgia
It is difficult to develop pharmaceutical agents for treating fibromyalgia since both the pathogenetic cause and the onset mechanism remain to be clarified. An antirheumatic agent...
|
|
|
US20090280112 |
INHIBITORY EFFECTS OF NORDIHYDROGUAIARETIC ACID (NDGA) ON THE IGF-1 RECEPTOR AND ANDROGEN DEPENDENT GROWTH OF LAPC-4 PROSTATE CANCER CELLS
Disclosed herein are methods and compositions for the treatment of prostate cancer with an IGF-1 receptor kinase inhibitor. Methods are also provided for the treatment of prostate cancer by...
|
|
|
US20090275541 |
Method for treating neurocognitive dysfunction
A method of treating corticosteroid-induced cognitive impairment comprises administering an effective amount of at least one compound of formula I, or pharmaceutically acceptable salts thereof, to...
|
|
|
US20090275515 |
2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the...
|
|
|
US20090274730 |
COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION
Provided are electrokinetically-generated fluids (e.g., gas-enriched electrokinetic fluids or solutions), and therapeutic compositions and methods for use in treating inflammation or at least one...
|
|
|
US20090274676 |
COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A PDE-4 INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent...
|
|
|
US20090270355 |
Compounds
The present invention relates to a compound which is N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)etha
nesulfonamide
and salts thereof, processes for its preparation, to compositions...
|
|
|
US20090264390 |
Topical Personal Care Compositions And Methods of Use
Topical personal care compositions comprising an anti-inflammatory agent, a surfactant, a bodifier/humectant, and water and methods of use are disclosed.
|
|
|
US20090264389 |
Method of preparing dry powder inhalation compositions
The invention provides a method of preparing a dry powder inhalation composition comprising a pharmaceutically acceptable particulate carrier, a first particulate inhalant medicament and a second...
|
|
|
US20090264388 |
Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells
The present invention relates to neurokinin-1 (NK-1) receptor antagonists in combination with an inhibitor of metachromatic cell activation, such as an anti-inflammatory agent, an immunosuppressor,...
|
|
|
US20090263341 |
SOFT ANTICHOLINERGIC ESTERS
Soft anticholinergic esters of the formulas:
wherein R 1 and R 2 are both phenyl or one of R 1 and R 2 is phenyl and the other is cyclopentyl; R is C 1 -C 8 alkyl, straight or branched...
|
|
|
US20090263333 |
Pharmaceutical compounds and compositions
The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. Crystalline levosalbutamol sulphate Form I is characterised by a...
|
|
|
US20090258847 |
Cholanic Acid Amides
4-(3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phena
nthren-17-yl)-pentanoic acid amides wherein the nitrogen of the amide group is substituted by a sulfonylaminocarbonyl-(C 1-4 )-alkyl...
|
|
|
US20090258846 |
Eyebrow re-growth stimulator for re-growth of lost eyebrows
A chemical composition and method of an eyebrow re-growth stimulator for women who has lost there eyebrows due to dease and treatments. The lose of harmons and other causes such as in ageing women...
|
|
|
US20090258094 |
XANTHOHUMOL-ENRICHED HOP EXTRACT
A method for preparing a xanthohumol-rich hop composition. The method includes providing a solution that contains xanthohumol-containing hop substances and effecting precipitation of...
|
|
|
US20090258069 |
Delivery of LFA-1 antagonists to the gastrointestinal system
The present invention provides compositions and methods for treating disorders and diseases by delivery of LFA-1 antagonists to the gastrointestinal system. Methods include delivery of LFA-1...
|
|
|
US20090258046 |
COMPOSITION, FORMULATIONS AND KIT FOR TREATMENT OF RESPIRATORY AND LUNG DISEASE WITH NON-GLUCOCORTICOID STEROIDS AND/OR UBIQUINONE AND A BRONCHODILATING AGENT
A pharmaceutical or veterinary composition, which comprises a first active agent selected from a non-glucocorticoid steroid or analogues, a ubiquinone, or salts thereof, and a second active agent...
|
|
|
US20090257969 |
SOFT ANTICHOLINERGIC ZWITTERIONS
Soft anticholinergic zwitterions of the formulas:
wherein R 1 and R 2 are both phenyl or one of R 1 and R 2 is phenyl and the other is cyclopentyl; and wherein each asterisk marks a chiral...
|
|
|
US20090253665 |
METHOD OF TREATMENT OF DISEASE USING AN ADENOSINE A1 RECEPTOR ANTAGONIST AND AN ALDOSTERONE INHIBITOR
Pharmaceutical compositions comprising an aldosterone inhibitor and an adenosine A 1 receptor antagonist (AA 1 RA) and methods of treating cardiovascular disease comprising identifying a patient...
|
|
|
US20090253664 |
COMBINATION ANDOLAST/GLUCOCORTICOIDS
The invention relates to the combination of Andolast, a calcium-activated potassium channel opener and glucocorticoids for the treatment of patients suffering for airway diseases. Pharmaceutical...
|
|
|
US20090253663 |
SKIN EXTERNAL PREPARATION CONTAINING TRITERPENIC ACID
Disclosed is a skin external preparation containing a triterpenic acid typified by ursolic acid. For obtaining a skin external preparation having excellent storage stability by improving the...
|
|
|
US20090253662 |
GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM
The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the...
|
|
|
US20090247494 |
Omega-3 essential fatty acid composition and method for treatment of anal and colon-rectal disorders
I have developed a unique pharmaceutical composition containing Omega-3 essential fatty acids and advantageously an optional corticosteroid and/or topical anesthetic. The composition is useful in a...
|
|
|
US20090238771 |
PHARMACEUTICAL FORMULATIONS
An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent comprising said...
|
|
|
US20090232886 |
ORAL DOSAGE COMBINATION PHARMACEUTICAL PACKAGING
Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical formulation...
|
|
|
US20090227550 |
CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATION OF NEUROTRANSMITTERS
This invention relates to a galenical gel formulation for nasal administration of neurotransmitters/neuromodulators such as dopamine, serotonin or pregnenolone and progesterone. The special...
|
|
|
US20090227549 |
Fulvestrant formulations
Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed.
|
|
|
US20090227548 |
Novel Glucocorticoid Receptor Agonists
This Invention Relates To Novel Glucocorticoid Receptor Agonists of Formula (I):
and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical...
|
|
|
US20090227547 |
Novel salt form of a Beta2-adrenergic agonist quinolin-2-one derivative
A 2,5-dichlorobenzenesulfonate salt of compound (I):
is disclosed along with formulations thereof, processes for making the same, and methods of treatment or prophylaxis administering the same.
|
|
|
US20090226431 |
Treatment of Cancer and Other Diseases
The present invention relates to a novel compound (e.g., 24-ethyl-cholestane-3β,5α,6α-triol), its production, its use, and to methods of treating neoplasms and other tumors as well as other...
|
|
|
US20090226379 |
BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS
This invention provides compounds of formula I:
wherein a, b, c, d, m, n, p, s, t, W, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 are as defined in the specification. The compounds of...
|
|
|
US20090221541 |
PHARMACEUTICAL FORMULATIONS
An aspect of the present invention provides for a medicament suitable for administration as a nasal inhalant including an aqueous carrier and suspended therein particulate pleconaril, the aqueous...
|
|
|
US20090221540 |
Method of Treating An Acute Vascular Disorder
The invention relates to a method of treating an acute vascular disorder in a mammal. The method comprises orally administering to the mammal an effective amount of a steroid. The steroid is...
|
|
|
US20090221539 |
METHOD OF DETECTING AND REDUCING BOAR TAINT USING NUCLEAR RECEPTORS
A method for preventing or reducing boar taint, a method of screening pigs to determine those more likely to have reduced boar taint and a method for screening substances that enhance skatole...
|
|
|
US20090221503 |
USE OF RAPAMYCIN AND RAPAMYCIN DERIVATIVES FOR THE TREATMENT OF BONE LOSS
The present invention relates to a new use of rapamycin and rapamycin derivatives.
|
|
|
US20090220435 |
TIGHT JUNCTION MODULATING PEPTIDE COMPONENTS FOR ENHANCING MUCOSAL DELIVERY OF THERAPEUTIC AGENTS
Compounds and components including sequences for mucosal epithelial transport of an active agent are given. Tight junction modulating peptide components are described for use in transport and...
|
|
|
US20090215735 |
TOPICAL SOLUTION FORMULATIONS CONTAINING A CORTICOSTEROID AND A CYCLODEXTRIN
Solution formulations containing a corticosteroid, cyclodextrin, and xanthan gum are disclosed. The formulations are intended for topical application to the eye, ear, or nose.
|
|
|
US20090215734 |
METHOD AND SYSTEM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED ANTICHOLINERGIC ADMINISTRATIONS
Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as COPD, are provided.
|
|
|
US20090215733 |
THERAPY FOR THE PROPHYLAXIS OR TREATMENT OF ADVERSE BODY COMPOSITION CHANGES AND/OR DECREASED MUSCLE STRENGTH AFTER ANDROGEN OR GNRH ANALOGUE INTAKE
Methods of treating or reducing the risk of one or more effects or signs of induced hypogonadism after androgen or GnRH intake are disclosed herein. In an embodiment, a method of treating one or...
|
|
|
US20090215732 |
COMBINATION OF COMPOUNDS, WHICH CAN BE USED IN THE TREATMENT OF RESPIRATORY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA
The present invention provides pharmaceutical compositions comprising a glucocorticosteroid and a compound of formula: wherein m, R 1 , R 2 , R 3 , and R 4 are as defined in the specification, and...
|
|
|
US20090215731 |
Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with...
|
|
|
US20090209574 |
FLUOROQUINOLONE DERIVATIVES FOR OPHTHALMIC APPLICATIONS
The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The...
|